Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial
BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho. METH...
Gespeichert in:
Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2020-11, Vol.85 (3), p.280-291 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 291 |
---|---|
container_issue | 3 |
container_start_page | 280 |
container_title | Journal of acquired immune deficiency syndromes (1999) |
container_volume | 85 |
creator | Tukei, Betty B. Fatti, Geoffrey Tiam, Appolinaire Ngorima-Mabhena, Nicoletta Tukei, Vincent J. Tshabalala, Itumeleng Sejana, Veronica M. Muzenda, Trish Mokoroane, Lincoln M. Sehlabo, Lebelang Maotoe, Thapelo Mirembe, Justine K. Membe, Ian Akpan, Francis Maile, Khotso Faturiyele, Iyiola Xulu, Thembi Minior, Thomas Sanne, Ian Chasela, Charles |
description | BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho.
METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370).
RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively.
CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model. |
doi_str_mv | 10.1097/QAI.0000000000002439 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424102350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507461342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</originalsourceid><addsrcrecordid>eNqFks1uEzEUhS0EoiXwBghZYsPGxb_zw26aAo2UUFEitiPPzHXj4hkHe4aovBfvh9MUhLoo3tjW_c65Vz5G6CWjJ4yW-dvP1eKE_rO4FOUjdMxKKUleFPJxOiuuiGRCHaFnMV5TyjIpy6foSPAsUzKjx-jXegfuB5CVH8YNvpjG1vcQsTd47vt-Gux4Q051hA6fWWMgwDBaPabrynfgbsHV5Ebb3-rPbNzCEO1wtS9Ul2tcpcIV_jLqxgE-X3wli8FAuzeouqSL2A54CdGPG_8OV3jupjhCIJd66Hxvfybukx9s0gTrQxoGr4PV7jl6YrSL8OJun6H1h_fr-TlZXnxczKslaRUVJWnyomVUNE3TGslLkxnIZa4VU0YVipmCKwqGd43MGWN53ma5Fg1tFHQFYyBm6M3Bdhv89wniWPc2tuCcHsBPseaSS0a5SM1m6PU99NpPYUjD1alJLjMmJH-QkkqyMitTXDMkD1QbfIwBTL0Nttfhpma03mdfp-zr-9kn2as786npofsr-hN2AooDsPMuPXL85qYdhHoD2o2b_3nLB6TpY_FMCEk45ZQxyijZKzPxGwihyus</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454196941</pqid></control><display><type>article</type><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><creator>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles</creator><creatorcontrib>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles ; for EQUIP Health</creatorcontrib><description>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho.
METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370).
RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively.
CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000002439</identifier><identifier>PMID: 32665460</identifier><language>eng</language><publisher>United States: JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher><subject>Adolescent ; Adult ; Adults ; AIDS/HIV ; Anti-HIV Agents - economics ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Cluster Analysis ; Clustering ; Confidence intervals ; Dispensing ; Drug Prescriptions ; Female ; Health Care Costs ; Health Facilities ; Health Services Accessibility ; HIV ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Lesotho ; Male ; Middle Aged ; Patient Compliance ; Retention ; Risk management ; Viral Load ; Young Adult</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2020-11, Vol.85 (3), p.280-291</ispartof><rights>JAIDS Journal of Acquired Immune Deficiency Syndromes</rights><rights>Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright Lippincott Williams & Wilkins Ovid Technologies Nov 1, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</citedby><cites>FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00126334-202011010-00006$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,777,781,4595,27905,27906,65212</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32665460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tukei, Betty B.</creatorcontrib><creatorcontrib>Fatti, Geoffrey</creatorcontrib><creatorcontrib>Tiam, Appolinaire</creatorcontrib><creatorcontrib>Ngorima-Mabhena, Nicoletta</creatorcontrib><creatorcontrib>Tukei, Vincent J.</creatorcontrib><creatorcontrib>Tshabalala, Itumeleng</creatorcontrib><creatorcontrib>Sejana, Veronica M.</creatorcontrib><creatorcontrib>Muzenda, Trish</creatorcontrib><creatorcontrib>Mokoroane, Lincoln M.</creatorcontrib><creatorcontrib>Sehlabo, Lebelang</creatorcontrib><creatorcontrib>Maotoe, Thapelo</creatorcontrib><creatorcontrib>Mirembe, Justine K.</creatorcontrib><creatorcontrib>Membe, Ian</creatorcontrib><creatorcontrib>Akpan, Francis</creatorcontrib><creatorcontrib>Maile, Khotso</creatorcontrib><creatorcontrib>Faturiyele, Iyiola</creatorcontrib><creatorcontrib>Xulu, Thembi</creatorcontrib><creatorcontrib>Minior, Thomas</creatorcontrib><creatorcontrib>Sanne, Ian</creatorcontrib><creatorcontrib>Chasela, Charles</creatorcontrib><creatorcontrib>for EQUIP Health</creatorcontrib><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho.
METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370).
RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively.
CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - economics</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Cluster Analysis</subject><subject>Clustering</subject><subject>Confidence intervals</subject><subject>Dispensing</subject><subject>Drug Prescriptions</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Health Facilities</subject><subject>Health Services Accessibility</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Lesotho</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Retention</subject><subject>Risk management</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1uEzEUhS0EoiXwBghZYsPGxb_zw26aAo2UUFEitiPPzHXj4hkHe4aovBfvh9MUhLoo3tjW_c65Vz5G6CWjJ4yW-dvP1eKE_rO4FOUjdMxKKUleFPJxOiuuiGRCHaFnMV5TyjIpy6foSPAsUzKjx-jXegfuB5CVH8YNvpjG1vcQsTd47vt-Gux4Q051hA6fWWMgwDBaPabrynfgbsHV5Ebb3-rPbNzCEO1wtS9Ul2tcpcIV_jLqxgE-X3wli8FAuzeouqSL2A54CdGPG_8OV3jupjhCIJd66Hxvfybukx9s0gTrQxoGr4PV7jl6YrSL8OJun6H1h_fr-TlZXnxczKslaRUVJWnyomVUNE3TGslLkxnIZa4VU0YVipmCKwqGd43MGWN53ma5Fg1tFHQFYyBm6M3Bdhv89wniWPc2tuCcHsBPseaSS0a5SM1m6PU99NpPYUjD1alJLjMmJH-QkkqyMitTXDMkD1QbfIwBTL0Nttfhpma03mdfp-zr-9kn2as786npofsr-hN2AooDsPMuPXL85qYdhHoD2o2b_3nLB6TpY_FMCEk45ZQxyijZKzPxGwihyus</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Tukei, Betty B.</creator><creator>Fatti, Geoffrey</creator><creator>Tiam, Appolinaire</creator><creator>Ngorima-Mabhena, Nicoletta</creator><creator>Tukei, Vincent J.</creator><creator>Tshabalala, Itumeleng</creator><creator>Sejana, Veronica M.</creator><creator>Muzenda, Trish</creator><creator>Mokoroane, Lincoln M.</creator><creator>Sehlabo, Lebelang</creator><creator>Maotoe, Thapelo</creator><creator>Mirembe, Justine K.</creator><creator>Membe, Ian</creator><creator>Akpan, Francis</creator><creator>Maile, Khotso</creator><creator>Faturiyele, Iyiola</creator><creator>Xulu, Thembi</creator><creator>Minior, Thomas</creator><creator>Sanne, Ian</creator><creator>Chasela, Charles</creator><general>JAIDS Journal of Acquired Immune Deficiency Syndromes</general><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20201101</creationdate><title>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</title><author>Tukei, Betty B. ; Fatti, Geoffrey ; Tiam, Appolinaire ; Ngorima-Mabhena, Nicoletta ; Tukei, Vincent J. ; Tshabalala, Itumeleng ; Sejana, Veronica M. ; Muzenda, Trish ; Mokoroane, Lincoln M. ; Sehlabo, Lebelang ; Maotoe, Thapelo ; Mirembe, Justine K. ; Membe, Ian ; Akpan, Francis ; Maile, Khotso ; Faturiyele, Iyiola ; Xulu, Thembi ; Minior, Thomas ; Sanne, Ian ; Chasela, Charles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5039-b78c103bbbcf429f6fe747a515f5851f8250ef2db4711177c67a3b0b5ed811e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - economics</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Cluster Analysis</topic><topic>Clustering</topic><topic>Confidence intervals</topic><topic>Dispensing</topic><topic>Drug Prescriptions</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Health Facilities</topic><topic>Health Services Accessibility</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Lesotho</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Retention</topic><topic>Risk management</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tukei, Betty B.</creatorcontrib><creatorcontrib>Fatti, Geoffrey</creatorcontrib><creatorcontrib>Tiam, Appolinaire</creatorcontrib><creatorcontrib>Ngorima-Mabhena, Nicoletta</creatorcontrib><creatorcontrib>Tukei, Vincent J.</creatorcontrib><creatorcontrib>Tshabalala, Itumeleng</creatorcontrib><creatorcontrib>Sejana, Veronica M.</creatorcontrib><creatorcontrib>Muzenda, Trish</creatorcontrib><creatorcontrib>Mokoroane, Lincoln M.</creatorcontrib><creatorcontrib>Sehlabo, Lebelang</creatorcontrib><creatorcontrib>Maotoe, Thapelo</creatorcontrib><creatorcontrib>Mirembe, Justine K.</creatorcontrib><creatorcontrib>Membe, Ian</creatorcontrib><creatorcontrib>Akpan, Francis</creatorcontrib><creatorcontrib>Maile, Khotso</creatorcontrib><creatorcontrib>Faturiyele, Iyiola</creatorcontrib><creatorcontrib>Xulu, Thembi</creatorcontrib><creatorcontrib>Minior, Thomas</creatorcontrib><creatorcontrib>Sanne, Ian</creatorcontrib><creatorcontrib>Chasela, Charles</creatorcontrib><creatorcontrib>for EQUIP Health</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tukei, Betty B.</au><au>Fatti, Geoffrey</au><au>Tiam, Appolinaire</au><au>Ngorima-Mabhena, Nicoletta</au><au>Tukei, Vincent J.</au><au>Tshabalala, Itumeleng</au><au>Sejana, Veronica M.</au><au>Muzenda, Trish</au><au>Mokoroane, Lincoln M.</au><au>Sehlabo, Lebelang</au><au>Maotoe, Thapelo</au><au>Mirembe, Justine K.</au><au>Membe, Ian</au><au>Akpan, Francis</au><au>Maile, Khotso</au><au>Faturiyele, Iyiola</au><au>Xulu, Thembi</au><au>Minior, Thomas</au><au>Sanne, Ian</au><au>Chasela, Charles</au><aucorp>for EQUIP Health</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>85</volume><issue>3</issue><spage>280</spage><epage>291</epage><pages>280-291</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>BACKGROUND:Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho.
METHODS:Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.govNCT03438370).
RESULTS:A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI)−1.6% to 1.5%], adjusted RD = −1.3% (95% CI−3.0% to 0.5%), and adjusted RD = −1.2% (95% CI−2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI0.98 to 1.01) and RR = 1.00 (95% CI0.98 to 1.01), respectively.
CONCLUSIONS:There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.</abstract><cop>United States</cop><pub>JAIDS Journal of Acquired Immune Deficiency Syndromes</pub><pmid>32665460</pmid><doi>10.1097/QAI.0000000000002439</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1525-4135 |
ispartof | Journal of acquired immune deficiency syndromes (1999), 2020-11, Vol.85 (3), p.280-291 |
issn | 1525-4135 1944-7884 |
language | eng |
recordid | cdi_proquest_miscellaneous_2424102350 |
source | MEDLINE; Journals@Ovid LWW Legacy Archive; Free E- Journals |
subjects | Adolescent Adult Adults AIDS/HIV Anti-HIV Agents - economics Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Cluster Analysis Clustering Confidence intervals Dispensing Drug Prescriptions Female Health Care Costs Health Facilities Health Services Accessibility HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Lesotho Male Middle Aged Patient Compliance Retention Risk management Viral Load Young Adult |
title | Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T04%3A17%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Twelve-Month%20Outcomes%20of%20Community-Based%20Differentiated%20Models%20of%20Multimonth%20Dispensing%20of%20ART%20Among%20Stable%20HIV-Infected%20Adults%20in%20Lesotho:%20A%20Cluster-Randomized%20Noninferiority%20Trial&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Tukei,%20Betty%20B.&rft.aucorp=for%20EQUIP%20Health&rft.date=2020-11-01&rft.volume=85&rft.issue=3&rft.spage=280&rft.epage=291&rft.pages=280-291&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000002439&rft_dat=%3Cproquest_cross%3E2507461342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454196941&rft_id=info:pmid/32665460&rfr_iscdi=true |